Repeated exposure to trace amounts of woodchuck hepadnavirus induces molecularly evident infection and virus-specific T cell response in the absence of serological infection markers and hepatitis

Journal of Virology

Volumn 87, Issue 2, 2013, Pages 1035-1048

  Gujar, Shashi A ^a,b   Mulrooney Cousins, Patricia M ^a   Michalak, Tomasz I ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MITOGENIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ALPHA INTERFERON GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GAMMA INTERFERON GENE; GENE; GENE EXPRESSION; HEPADNAVIRUS; HEPADNAVIRUS INFECTION; HEPATITIS B; INTERLEUKIN 10 GENE; INTERLEUKIN 12 GENE; INTERLEUKIN 2 GENE; INTERLEUKIN 4 GENE; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MALE; MICROBIAL KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROVOCATION TEST; REPEATED VIRUS EXPOSURE; SEROLOGY; T LYMPHOCYTE; TUMOR NECROSIS FACTOR ALPHA GENE; VIRION; VIRUS CELL INTERACTION; VIRUS INFECTION; WOODCHUCK; WOODCHUCK HEPATITIS; WOODCHUCK HEPATITIS VIRUS;

ANIMALS; ASYMPTOMATIC DISEASES; DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS, WOODCHUCK; MARMOTA; T-LYMPHOCYTES;

ANIMALIA; HEPADNAVIRIDAE; HEPATITIS B VIRUS; MARMOTA MONAX; WOODCHUCK HEPATITIS VIRUS;

EID: 84871971613     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01363-12     Document Type: Article

References (77)

1. Bes M, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, Pinacho A, Quer J, Puig L, Guardia J, Sauleda S. 2012. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J. Hepatol. 56:765-774.
2. Fang Y, Shang QL, Liu JY, Li D, Xu WZ, Teng X, Zhao HW, Fu LJ, Zhang FM, Gu HX. 2009. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J. Infect. 58: 383-388.
3. FitzSimons D, Francois G, De Carli G, Shouval D, Pruss-Ustun A, Puro V, Williams I, Lavanchy D, De Schryver A, Kopka A, Ncube F, Ippolito G, Van Damme P. 2008. Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries. Occup. Environ. Med. 65: 446-451.
4. MacCannell T, Laramie AK, Gomaa A, Perz JF. 2010. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies. Clin. Liver Dis. 14:23-36.
5. Michelin A, Henderson DK. 2010. Infection control guidelines for prevention of health care-associated transmission of hepatitis B and C viruses. Clin. Liver Dis. 14:119-136.
6. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. 2004. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39:51-57.
7. Menne S, Cote PJ. 2007. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J. Gastroenterol. 13:104-124.
8. Michalak TI. 2000. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol. Rev. 174:98-111.
9. Mulrooney-Cousins PM, Michalak TI. 2011. New aspects of natural history and pathogenicity of hepadnaviral infection and hepatocyte function revealed by the woodchuck model of hepatitis B, p 355-378. In Mizuguchi Y (ed), Liver biopsy in medicine. Intech, Rijeka, Croatia.
10. Coffin CS, Pham TN, Mulrooney PM, Churchill ND, Michalak TI. 2004. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology 40:1053-1061.
11. Gujar SA, Michalak TI. 2009. Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the woodchuck model of hepatitis B virus infection. J. Virol. 83:3861-3876.
12. Michalak TI, Mulrooney PM, Coffin CS. 2004. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J. Virol. 78:1730-1738.
13. Michalak TI, Pardoe IU, Coffin CS, Churchill ND, Freake DS, Smith P, Trelegan CL. 1999. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology 29:928-938.
14. Mulrooney-Cousins PM, Michalak TI. 2007. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J. Gastroenterol. 13:5682-5686.
15. Coffin CS, Michalak TI. 1999. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J. Clin. Invest. 104:203-212.
16. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G. 2008. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 134:1470-1481.
17. Challine D, Chevaliez S, Pawlotsky JM. 2008. Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors. Gastroenterology 135:1185-1191.
18. Firnhaber C, Chen CY, Evans D, Maskew M, Schulz D, Reyneke A, Kramvis A. 2012. Prevalence of hepatitis B virus (HBV) co-infection in HBV serologically-negative South African HIV patients and retrospective evaluation of the clinical course of mono-and co-infection. Int. J. Infect. Dis. 16:e268-e272.
19. Raimondo G, Pollicino T, Cacciola I, Squadrito G. 2007. Occult hepatitis B virus infection. J. Hepatol. 46:160-170. 20. Song EY, Yun YM, Park MH, Seo DH. 2009. Prevalence of occult hepatitis B virus infection in a general adult population in Korea. Intervirology 52:57-62.
20. Song EY, Yun YM, Park MH, Seo DH. 2009. Prevalence of occult hepatitis B virus infection in a general adult population in Korea. Intervirology 52:57-62
21. de la Fuente RA, Gutierrez ML, Garcia-Samaniego J, Fernandez-Rodriguez C, Lledo JL, Castellano G. 2011. Pathogenesis of occult chronic hepatitis B virus infection. World J. Gastroenterol. 17:1543-1548.
22. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F. 2008. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49:652-657.
23. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. 1994. Hepatitis B virus persistence after recovery from acute viral hepatitis. J. Clin. Invest. 93:230-239.
24. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. 1996. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2:1104-1108.
25. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M. 2003. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37:1172-1179.
26. Korba BE, Wells FV, Baldwin B, Cote PJ, Tennant BC, Popper H, Gerin JL. 1989. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 9:461-470.
27. Menne S, Cotte PI, Butler SD, Toshkov IA, Gerin JL, Tennant BC. 2007. Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection. Hepatology 54:614-622.
28. Hoofnagle JH. 2009. Reactivation of hepatitis B. Hepatology 49:S156-S165.
29. Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. 2011. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J. Gastroenterol. 17:3881-3887.
30. Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. 2012. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin. Res. Hepatol. Gastroenterol. 36:84-93.
31. Bertoletti A, Gehring AJ. 2006. The immune response during hepatitis B virus infection. J. Gen. Virol. 87:1439-1449.
32. Chisari FV. 1997. Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 99:1472-1477.
33. Dandri M, Locarnini S. 2012. New insight in the pathobiology of hepatitis B virus infection. Gut 61(Suppl 1):i6-i17.
34. Tan AT, Koh S, Goh V, Bertoletti A. 2008. Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective. J. Gastroenterol. Hepatol. 23:833-843.
35. Bertoletti A, Ferrari C. 2003. Kinetics of the immune responses during HBV and HCV infection. Hepatology 38:4-13.
36. Guidotti LG, Chisari FV. 2006. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1:23-61.
37. Gujar SA, Jenkins AK, Guy CS, Wang J, Michalak TI. 2008. Aberrant lymphocyte activation precedes delayed virus-specific T-cell response after both primary infection and secondary exposure to hepadnavirus in the woodchuck model of hepatitis B virus infection. J. Virol. 82: 6992-7008.
38. Gujar SA, Jenkins AK, MacParland SA, Michalak TI. 2010. Pre-acute hepadnaviral infection is associated with activation-induced apoptotic death of lymphocytes in the woodchuck (Marmota monax) model of hepatitis B. Dev. Comp. Immunol. 34:999-1008.
39. Hodgson PD, Michalak TI. 2001. Augmented hepatic interferon gamma expression and T-cell influx characterize acute hepatitis progressing to recovery and residual lifelong virus persistence in experimental adult woodchuck hepatitis virus infection. Hepatology 34:1049-1059.
40. Mulrooney-Cousins PM, Michalak TI. 2008. Repeated passage of wild-type woodchuck hepatitis virus in lymphoid cells does not generate cell type-specific variants or alter virus infectivity. J. Virol. 82: 7540-7550.
41. Gujar SA, Michalak TI. 2005. Flow cytometric quantification of T cell proliferation and division kinetics in woodchuck model of hepatitis B. Immunol. Invest. 34:215-236.
42. Guy CS, Mulrooney-Cousins PM, Churchill ND, Michalak TI. 2008. Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J. Virol. 82:8579-8591.
43. Michalak TI, Hodgson PD, Churchill ND. 2000. Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection. J. Virol. 74:4483-4494.
44. Michalak TI, Lin B, Churchill ND, Dzwonkowski P, Desousa JR. 1990. Hepadna virus nucleocapsid and surface antigens and the antigen-specific antibodies associated with hepatocyte plasma membranes in experimental woodchuck acute hepatitis. Lab. Invest. 62:680-689.
45. Wang J, Gujar SA, Cova L, Michalak TI. 2007. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J. Virol. 81:903-916.
46. Menne S, Maschke J, Lu M, Grosse-Wilde H, Roggendorf M. 1998. T-cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J. Virol. 72:6083-6091.
47. Menne S, Maschke J, Tolle T, Kreuzfelder E, Grosse-Wilde H, Roggendorf M. 1997. Determination of peripheral blood mononuclear cell responses to mitogens and woodchuck hepatitis virus core antigen in woodchucks by 5-bromo-2=-deoxyuridine or 2[3H]adenine incorporation. Arch. Virol. 142:511-521.
48. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, Williams R, Dusheiko G, Bertoletti A. 2004. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 78:5707-5719.
49. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Brown D, Amlot PL, Williams R, Vergani D, Dusheiko GM, Bertoletti A. 2000. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32:1117-1124.
50. Castellino F, Germain RN. 2006. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu. Rev. Immunol. 24:519-540.
51. Gourley TS, Wherry EJ, Masopust D, Ahmed R. 2004. Generation and maintenance of immunological memory. Semin. Immunol. 16:323-333.
52. Kaech SM, Wherry EJ, Ahmed R. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251-262.
53. De Boer RJ, Homann D, Perelson AS. 2003. Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J. Immunol. 171:3928-3935.
54. Khanolkar A, Fuller MJ, Zajac AJ. 2002. T cell responses to viral infections: lessons from lymphocytic choriomeningitis virus. Immunol. Res. 26:309-321.
55. Brown DM, Roman E, Swain SL. 2004. CD4 T cell responses to influenza infection. Semin. Immunol. 16:171-177.
56. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. 2003. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101:2686-2692.
57. Schlub TE, Sun JC, Walton SM, Robbins SH, Pinto AK, Munks MW, Hill AB, Brossay L, Oxenius A, Davenport MP. 2011. Comparing the kinetics of NK cells, CD4, and CD8 T cells in murine cytomegalovirus infection. J. Immunol. 187:1385-1392.
58. Manz BN, Jackson BL, Petit RS, Dustin ML, Groves J. 2011. T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters. Proc. Natl. Acad. Sci. U. S. A. 108:9089-9094.
59. Zehn D, Lee SY, Bevan MJ. 2009. Complete but curtailed T-cell response to very low-affinity antigen. Nature 458:211-214.
60. Tseng KE, Chung CY, H'ng WS, Wang SL. 2009. Early infection termination affects number of CD8+ memory T cells and protective capacities in listeria monocytogenes-infected mice upon rechallenge. J. Immunol. 182:4590-4600.
61. Williams MA, Bevan MJ. 2004. Shortening the infectious period does not alter expansion of CD8 T cells but diminishes their capacity to differentiate into memory cells. J. Immunol. 173:6694-6702.
62. Manicassamy S, Pulendran B. 2011. Dendritic cell control of tolerogenic responses. Immunol. Rev. 241:206-227.
63. Pulendran B, Tang H, Manicassamy S. 2010. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat. Immunol. 11:647-655.
64. Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, Rasenack J, Nakano T, Robertson B, Ismail A, Koziel MJ. 2004. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J. Virol. 78:12252-12258.
65. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. 1997. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J. Infect. Dis. 176:859-866.
66. Quiroga JA, Llorente S, Castillo I, Rodriguez-Inigo E, Pardo M, Carreno V. 2006. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J. Virol. 80:10972-10979.
67. Promadej N, Costello C, Wernett MM, Kulkarni PS, Robison VA, Nelson KE, Hodge TW, Suriyanon V, Duerr A, McNicholl JM. 2003. Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. J. Infect. Dis. 187:1053-1063.
68. Tasca S, Tsai L, Trunova N, Gettie A, Saifuddin M, Bohm R, Chakrabarti L, Cheng-Mayer C. 2007. Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure. Virology 367:196-211.
69. Andoniou CE, van Dommelen SL, Voigt V, Andrews DM, Brizard G, Asselin-Paturel C, Delale T, Stacey KJ, Trinchieri G, Degli-Esposti MA. 2005. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat. Immunol. 6:1011-1019.
70. Kawai T, Akira S. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7:131-137.
71. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. 2011. Pattern recognition receptors and the innate immune response to viral infection. Viruses 3:920-940.
72. Iwamoto S, Iwai S, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M, Masunaga A, Ogawa Y, Oguchi K, Miyazaki A. 2007. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J. Immunol. 179:1449-1457.
73. Reis e Sousa C, Sher A, Kaye P. 1999. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr. Opin. Immunol. 11:392-399.
74. Dauer M, Pohl K, Obermaier B, Meskendahl T, Robe J, Schnurr M, Endres S, Eigler A. 2003. Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation. Immunology 110:38-47.
75. McRae BL, Nagal T, Semnani RT, van Seventer JM, van Seventer GA. 2000. Interferon-alpha and-beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors. Blood 96:210-217.
76. Chen B, Shi Y, Smith JD, Choi D, Geiger JD, Mule JJ. 1998. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 91:4652-4661.
77. Kadowaki N, Antonenko S, Lau JY, Liu YJ. 2000. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J. Exp. Med. 192:219-226.